New Therapies on the Horizon for Elderly or Frail Patients With Head and Neck Cancer
A nanoparticle-radiotherapy regimen and a chemoimmunotherapy regimen both appear safe and effective for this population.
A nanoparticle-radiotherapy regimen and a chemoimmunotherapy regimen both appear safe and effective for this population.
Researchers evaluated the efficacy and safety of talazoparib in the neoadjuvant setting in a phase 2, nonrandomized, single-arm, open-label study.
Targeted therapy was associated with better survival with both ctDNA and tissue-only matched patients.
Dr Alan Lyss reviews results from the high-risk cohort of the WSG-ADAPT HR+/HER2- trial.
Most patients had at least 1 biomarker test, but only 46% had all 5 biomarker tests.
Responses were observed across EGFR TKI resistance mechanisms.
Durvalumab improved invasive disease-free survival, distant disease-free survival, and overall survival.
Data showed increases in endometrial cancer and obesity in women younger than 40.
Nearly three-quarters of patients responded to treatment.
The signature was prognostic for locoregional recurrence.